Table 2 Guidance characteristics
Organisation, Country | Title, year | Considered health technologies | Terminology | Definition | Harmonised Terminology according to Burford et al. [4] |
|---|---|---|---|---|---|
ACE Agency for care effectiveness, Singapore [17] | Medical Technologies Evaluation Methods and Process Guide Version 1.0, 2018 | non-pharmaceuticals (e.g. medical devices, diagnostics, medical services/ procedures) | Generalisability | That is, whether the results apply to wider patient groups (and over a longer follow-up), Asian populations, and to routine clinical practice in the local context | Generalisability/External Validity |
EUnetHTA European Network for Health Technology Assessment, Europe [18] | HTA Core Model Version 3.0, 2016 | generic (diagnostic technologies, medical interventions, surgical interventions, pharmaceuticals, screening technologies) | Transferability, generalisability | The extent to which the results of existing studies are likely to reflect the results expected in the population of interest in different jurisdictions or health systems | Transferability |
GÖG Gesundheit Österreich GmbH and LBI Ludwig Boltzmann Institut, Austria [19] | Methodenhandbuch für Health Technology Assessment Version 1.2012, 2012 | generic (health technologies) | Generalisability | Generalisability refers to the question, whether study results can be applied to another context [translated] | Generalisability/External Validity |
HIQA Health Information and Quality Authority, Ireland [20] | Guidelines for the Retrieval and Interpretation of Economic Evaluations of Health Technologies in Ireland, 2014 | generic (“drugs, equipment, diagnostic techniques and health promotion activities”) | Generalisability, transferability, transportability, external validity, relevance or applicability | The extent to which one can apply or extrapolate results obtained in one setting or population to another | Generalisability/External Validity |
HQA Health Quality Ontario, Canada [21] | Health Technology Assessments – Methods and Process Guide Version 2.0, 2018 | non-pharmaceuticals (e.g. medical device and health care services (e.g. medical devices, medical tests, surgical procedures, health care programs, complex health system interventions) | Applicability | NRb | NAa |
Generalisability | Generalisability refers to ‘the problem of whether one can apply or extrapolate results obtained in one setting or population to another.’ | Generalisability/External Validity | |||
NICE National Institute for Health and Care Excellence, England and Wales [22] | Developing NICE guidelines: the manual (PMG20), 2014 | generic (“from preventing and managing specific conditions, improving health, and managing medicines in different settings, to providing social care and support to adults and children, and planning broader services and interventions to improve the health of communities”) | Applicability | How well an observation or the results of a study or a review are likely to hold true in a particular setting/non-study settings/for another population or in a different context | Transferability |
SBU Swedish Agency for Health Technology Assessment and Assessment of Social Services, Sweden [23] | Assessment of methods in healthcare – a handbook, 2018 | generic (all interventions involving prevention, diagnosis, treatment or care) | Transferability | NR | NA |